Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2831581 | 0.82 | KMT2A (0.33) | LMNAL3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4938646 | 0.77 | CNR1 (0.33) | LMNA | |
| SCHEMBL4045422 | 0.77 | PKM (0.35) | LMNAMAPTSMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL4939489 | 0.76 | LMNA (0.33) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL23907994 | 0.76 | LMNA (0.46) | LMNAL3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14000740 | 0.76 | GLP1R (0.33) | LMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL4138601 | 0.73 | LMNA (0.32) | LMNAL3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6080008 | 0.73 | — | — | |
| SCHEMBL4932061 | 0.73 | MAPT (0.41) | LMNAL3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5164507 | 0.72 | NPC1 (0.34) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132522-A1 | 2-Substituted Pyrimidines, Method for Their Production and Their Use for Controlling Pathogenic Fungi | BASF AKTIENGESELLSCHAFT (DE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132522-A1 | 2-Substituted Pyrimidines, Method for Their Production and Their Use for Controlling Pathogenic Fungi | TYMS, TYMP, PNPO | LMNA 2500/4885L3MBTL1 700/4885MAPT 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.